These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32081303)

  • 1. [Aluminium adjuvant exposure through vaccines in France in 2018].
    Angrand L; Elnar AA; Authier FJ; Gherardi RK; Crépeaux G
    Ann Pharm Fr; 2020 Mar; 78(2):111-128. PubMed ID: 32081303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aluminum as an adjuvant in vaccines and post-vaccine reactions].
    Fiejka M; Aleksandrowicz J
    Rocz Panstw Zakl Hig; 1993; 44(1):73-80. PubMed ID: 8235346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health. Aluminum is put on trial as a vaccine booster.
    Malakoff D
    Science; 2000 May; 288(5470):1323-4. PubMed ID: 10847840
    [No Abstract]   [Full Text] [Related]  

  • 4. Aluminium-adjuvanted vaccines--a review of the current state of knowledge.
    Gołoś A; Lutyńska A
    Przegl Epidemiol; 2015; 69(4):731-4, 871-4. PubMed ID: 27139352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination.
    Mitkus RJ; King DB; Hess MA; Forshee RA; Walderhaug MO
    Vaccine; 2011 Nov; 29(51):9538-43. PubMed ID: 22001122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for granulomas in children following immunization with aluminium-adsorbed vaccines: A Danish population-based cohort study.
    Hoffmann SS; Thiesson EM; Johansen JD; Hviid A
    Contact Dermatitis; 2022 Nov; 87(5):430-438. PubMed ID: 35778959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reviewing the association between aluminum adjuvants in the vaccines and autism spectrum disorder.
    Boretti A
    J Trace Elem Med Biol; 2021 Jul; 66():126764. PubMed ID: 33930617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice.
    Freiberger SN; Leuthard DS; Duda A; Contassot E; Thallmair M; Kündig TM; Johansen P
    Eur J Pharm Sci; 2018 Mar; 115():362-368. PubMed ID: 29410031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The global impact of vaccines containing aluminium adjuvants.
    Clements CJ; Griffiths E
    Vaccine; 2002 May; 20 Suppl 3():S24-33. PubMed ID: 12184361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infants' exposure to aluminum from vaccines and breast milk during the first 6 months.
    Dórea JG; Marques RC
    J Expo Sci Environ Epidemiol; 2010 Nov; 20(7):598-601. PubMed ID: 20010978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminum salts in vaccines--US perspective.
    Baylor NW; Egan W; Richman P
    Vaccine; 2002 May; 20 Suppl 3():S18-23. PubMed ID: 12184360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical analysis of reference studies on the toxicokinetics of aluminum-based adjuvants.
    Masson JD; Crépeaux G; Authier FJ; Exley C; Gherardi RK
    J Inorg Biochem; 2018 Apr; 181():87-95. PubMed ID: 29307441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminum in vaccines: Does it create a safety problem?
    Principi N; Esposito S
    Vaccine; 2018 Sep; 36(39):5825-5831. PubMed ID: 30139653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aluminum vaccine adjuvants: are they safe?
    Tomljenovic L; Shaw CA
    Curr Med Chem; 2011; 18(17):2630-7. PubMed ID: 21568886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aluminum toxicokinetics regarding infant diet and vaccinations.
    Keith LS; Jones DE; Chou CH
    Vaccine; 2002 May; 20 Suppl 3():S13-7. PubMed ID: 12184359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cumulative and episodic vaccine aluminum exposure in a population-based cohort of young children.
    Glanz JM; Newcomer SR; Daley MF; McClure DL; Baxter RP; Jackson ML; Naleway AL; Lugg MM; DeStefano F
    Vaccine; 2015 Nov; 33(48):6736-44. PubMed ID: 26518400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of aluminum in hair of Brazilian infants and correlation to aluminum-adjuvanted vaccine exposure.
    Bohrer D; Schmidt M; Marques RC; Dórea JG
    Clin Chim Acta; 2014 Jan; 428():9-13. PubMed ID: 24183841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence.
    Jefferson T; Rudin M; Di Pietrantonj C
    Lancet Infect Dis; 2004 Feb; 4(2):84-90. PubMed ID: 14871632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myalgia and chronic fatigue syndrome following immunization: macrophagic myofasciitis and animal studies support linkage to aluminum adjuvant persistency and diffusion in the immune system.
    Gherardi RK; Crépeaux G; Authier FJ
    Autoimmun Rev; 2019 Jul; 18(7):691-705. PubMed ID: 31059838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.